The stock price of Cassava Sciences Inc (NASDAQ: SAVA) has plunged by -10.29 when compared to previous closing price of 3.84, but the company has seen a -86.99% decline in its stock price over the last five trading sessions. accesswire.com reported 2024-12-01 that NEW YORK, NY / ACCESSWIRE / December 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. (“Cassava Sciences, Inc.”) (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava “today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer’s Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
Is It Worth Investing in Cassava Sciences Inc (NASDAQ: SAVA) Right Now?
The 36-month beta value for SAVA is at -0.85. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SAVA is 41.77M, and currently, shorts hold a 43.29% of that float. The average trading volume for SAVA on December 03, 2024 was 4.26M shares.
SAVA’s Market Performance
SAVA stock saw a decrease of -86.99% in the past week, with a monthly decline of -86.65% and a quarterly a decrease of -87.69%. The volatility ratio for the week is 16.61%, and the volatility levels for the last 30 days are 11.97% for Cassava Sciences Inc (SAVA). The simple moving average for the past 20 days is -83.61% for SAVA’s stock, with a -84.65% simple moving average for the past 200 days.
Analysts’ Opinion of SAVA
H.C. Wainwright, on the other hand, stated in their research note that they expect to see SAVA reach a price target of $116. The rating they have provided for SAVA stocks is “Buy” according to the report published on October 08th, 2024.
SAVA Trading at -86.19% from the 50-Day Moving Average
After a stumble in the market that brought SAVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.84% of loss for the given period.
Volatility was left at 11.97%, however, over the last 30 days, the volatility rate increased by 16.61%, as shares sank -86.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -88.45% lower at present.
During the last 5 trading sessions, SAVA fell by -87.01%, which changed the moving average for the period of 200-days by -86.00% in comparison to the 20-day moving average, which settled at $21.02. In addition, Cassava Sciences Inc saw -84.70% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SAVA starting from Schoen, Eric J. (SAVA), who proposed sale 2,000 shares at the price of $3.82 back on Nov 29 ’24. After this action, Schoen, Eric J. (SAVA) now owns shares of Cassava Sciences Inc, valued at $7,640 using the latest closing price.
Schoen Eric, the Officer of Cassava Sciences Inc, proposed sale 59,800 shares at $3.86 during a trade that took place back on Nov 29 ’24, which means that Schoen Eric is holding shares at $230,966 based on the most recent closing price.
Stock Fundamentals for SAVA
Current profitability levels for the company are sitting at:
- -59.86 for the present operating margin
- 0.59 for the gross margin
The net margin for Cassava Sciences Inc stands at -7.52. The total capital return value is set at -0.84. Equity return is now at value -10.98, with -8.91 for asset returns.
Currently, EBITDA for the company is -95.69 million with net debt to EBITDA at 1.12. When we switch over and look at the enterprise to sales, we see a ratio of 7.14. The receivables turnover for the company is 0.37for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.55.
Conclusion
In conclusion, Cassava Sciences Inc (SAVA) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
